Economic Burden Associated with the Treatment with a Cardiovascular Polypill in Secondary Prevention in Spain: Cost-Effectiveness Results of the NEPTUNO Study.
Alberto CorderoRegina Dalmau González-GallarzaLluis MasanaValentín FusterJose Mª CastellanoJosé Emilio Ruiz OlivarIlonka ZsoltAntoni Sicras MainarJose Ramón González JuanateyPublished in: ClinicoEconomics and outcomes research : CEOR (2023)
CNIC-Polypill reduces recurrent major cardiovascular events and costs, being a cost-saving strategy as secondary prevention of ASCVD.